Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lan Deng

Showing results (221-230 of 230) with videos related to

Pageof 23
Sort By:
You have reached the last page of results.This site can display upto 230 results.
Neurocritical Care|March 29, 2020
Intraventricular Hemorrhage Growth: Definition, Prevalence and Association with Hematoma Expansion and PrognosisQi Li, Rui Li, Li-Bo Zhao, et al.
Nature Communications|November 29, 2025
Room-temperature valley-selective emission in Si-MoSe<sub>2</sub> heterostructures enabled by high-quality-factor chiroptical cavitiesFeng Pan, Xin Li, Amalya C Johnson, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
Oxidative Medicine and Cellular Longevity|September 23, 2021
Early Perihematomal Edema Expansion: Definition, Significance, and Association with Outcomes after Intracerebral HemorrhageXin-Ni Lv, Zuo-Qiao Li, Lan Deng, et al.
Cell Reports|June 8, 2024
Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1Zhou Tong, Jianyu Tong, Wenwen Lei, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Signal Transduction and Targeted Therapy|September 13, 2023
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort studyRuoyang Shao, Yu Zhang, Jinping He, et al.
Pageof 23

Showing results (221-230 of 230) with videos related to

Sort By:
Pageof 23
You have reached the last page of results.This site can display upto 230 results.
Neurocritical Care|March 29, 2020
Intraventricular Hemorrhage Growth: Definition, Prevalence and Association with Hematoma Expansion and PrognosisQi Li, Rui Li, Li-Bo Zhao, et al.
Nature Communications|November 29, 2025
Room-temperature valley-selective emission in Si-MoSe<sub>2</sub> heterostructures enabled by high-quality-factor chiroptical cavitiesFeng Pan, Xin Li, Amalya C Johnson, et al.
The Lancet. Oncology|August 14, 2020
Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trialLi Xuan, Yu Wang, Fen Huang, et al.
Oxidative Medicine and Cellular Longevity|September 23, 2021
Early Perihematomal Edema Expansion: Definition, Significance, and Association with Outcomes after Intracerebral HemorrhageXin-Ni Lv, Zuo-Qiao Li, Lan Deng, et al.
Cell Reports|June 8, 2024
Deciphering a reliable synergistic bispecific strategy of rescuing antibodies for SARS-CoV-2 escape variants, including BA.2.86, EG.5.1, and JN.1Zhou Tong, Jianyu Tong, Wenwen Lei, et al.
Journal of Hematology & Oncology|April 29, 2023
Venetoclax Combined with Azacitidine and Homoharringtonine in Relapsed/Refractory AML: A Multicenter, Phase 2 TrialHua Jin, Yu Zhang, Sijian Yu, et al.
The Lancet. Haematology|July 6, 2023
Sorafenib maintenance after allogeneic haemopoietic stem-cell transplantation in patients with FLT3-ITD acute myeloid leukaemia: long-term follow-up of an open-label, multicentre, randomised, phase 3 trialLi Xuan, Yu Wang, Kaibo Yang, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 9, 2022
Busulfan Plus Cyclophosphamide Versus Total Body Irradiation Plus Cyclophosphamide for Adults Acute B Lymphoblastic Leukemia: An Open-Label, Multicenter, Phase III TrialHaiyan Zhang, Zhiping Fan, Fen Huang, et al.
Journal of Internal Medicine|October 29, 2023
Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3-ITD: A multicenter phase 2 studySijian Yu, Yu Zhang, Guopan Yu, et al.
Signal Transduction and Targeted Therapy|September 13, 2023
Impact of genetic patterns on sorafenib efficacy in patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation: a multi-center, cohort studyRuoyang Shao, Yu Zhang, Jinping He, et al.
Pageof 23